Published in Ter Arkh on January 01, 1985
Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol (2010) 0.96
[C-reactive protein--marker of inflammation in atherosclerosis (new data)]. Kardiologiia (2002) 0.88
[Investigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova (1999) 0.87
Lack of association between three vascular endothelial growth factor gene polymorphisms and systemic sclerosis: results from a multicenter EUSTAR study of European Caucasian patients. Ann Rheum Dis (2006) 0.83
[Neopterin: new immunological marker of autoimmune rheumatic disease]. Klin Med (Mosk) (2000) 0.83
[Evaluation of methotrexate effect on the acute-phase response in rheumatoid arthritis after 12-week treatment]. Klin Med (Mosk) (2014) 0.82
[Anti-phosphatidylethanolamine antibodies in patients with Sneddon's syndrome]. Klin Med (Mosk) (2005) 0.82
[Cardiolipin antibodies in acute rheumatic fever]. Klin Med (Mosk) (1992) 0.82
[The efficiency and safety of adalimumab treatment in patients with active rheumatoid arthritis unresponsive to standard therapy: Russian national study results]. Ter Arkh (2012) 0.81
[Prevalence of mental disorders in SLE patients: correlations with the disease activity and comorbid chronic conditions]. Ter Arkh (2009) 0.80
[Cardiac rhythm and conduction disorders in polymyositis and dermatomyositis]. Klin Med (Mosk) (1998) 0.80
[Cardiolipin antibodies in patients with myocardial infarction and unstable angina pectoris]. Kardiologiia (1992) 0.80
C3a and C5a anaphylatoxins bind to heparin-based sorbent in low density lipoprotein apheresis: in vitro and in vivo investigations. Artif Organs (1992) 0.80
[Effect of small-dose glucocorticoids on the course of early rheumatic arthritis]. Klin Med (Mosk) (2004) 0.79
[Structum (chondroitin sulfate)--a new agent for the treatment of osteoarthrosis]. Ter Arkh (1999) 0.78
[Serum neopterin in hepatitis B]. Klin Med (Mosk) (1992) 0.78
[Synovial membrane in the early stage of rheumatoid arthritis: clinico-morphological comparisons]. Ter Arkh (2003) 0.78
[New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)]. Ter Arkh (2010) 0.78
[Corticosteroid therapy and aseptic bone necrosis in patients with rheumatoid arthritis]. Ter Arkh (1995) 0.78
[The von Willebrand factor antigen in patients with rheumatoid arthritis: a method for its determination and the clinical significance]. Ter Arkh (1993) 0.77
[Serum nitrates in patients with systemic lupus erythematosus and antiphospholipid syndrome]. Ter Arkh (2004) 0.77
[Clinical implication of assessment of heart rate variability in patients with psoriatic arthritis]. Ter Arkh (2009) 0.77
[Cardiovascular diseases in rheumatoid arthritis]. Ter Arkh (2007) 0.77
[Efficacy of colloid bismuth subcitrate (De-Nol) in gastropathies induced by nonsteroid anti-inflammatory drugs: an open controlled 4-week trial]. Ter Arkh (2005) 0.77
[Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis]. Ter Arkh (2013) 0.77
[The importance of cytokine profile characteristics for evaluating the therapeutic effectiveness of monoclonal antibodies against IL-6 receptors in patients with rheumatoid arthritis]. Klin Med (Mosk) (2014) 0.77
[The magnitude of fatigue and its association with depression, pain, and inflammatory activity in rheumatoid arthritis]. Ter Arkh (2013) 0.77
[Role of antiphospholipid antibodies in occlusion of retinal vessels in various vascular eye diseases]. Vestn Oftalmol (2002) 0.77
[Prospects for the assessment of cardiac rhythm variability in patients with rheumatoid arthritis and systemic lupus erythematosus]. Vestn Ross Akad Med Nauk (2010) 0.77
[Pulse therapy with methylprednisolone and cyclophosphamide in systemic juvenile rheumatoid arthritis: the results of an open, parallel, controlled, randomized, 12-month study]. Ter Arkh (1992) 0.77
[Cardiological aspects of the antiphospholipid syndrome. Part I. Valvular lesions in the primary and secondary antiphospholipid syndrome and systemic lupus erythematosus]. Kardiologiia (2002) 0.77
[Soluble adhesion molecules (P-selectin, ICAM-1 and ICAM-3) in rheumatoid arthritis]. Ter Arkh (1999) 0.76
[Soluble receptors of TNF-alpha with molecular mass 55 kDa in rheumatoid arthritis: clinical role]. Klin Med (Mosk) (2003) 0.76
[Antibodies to beta2-glycoprotein I in systemic lupus erythematosus: new laboratory marker of antiphospholipid syndrome]. Klin Med (Mosk) (1998) 0.76
[Human pathologies associated with mutations of mitochondrial genome]. Patol Fiziol Eksp Ter (2012) 0.76
[Soluble receptors of TNF-alpha in rheumatoid arthritis]. Klin Med (Mosk) (2001) 0.76
[The clinical significance of neopterin in human diseases]. Ter Arkh (1993) 0.76
Eosinophilic fasciitis. Review and report of six cases. Scand J Rheumatol (1979) 0.76
[The functional activity and count of the natural killer cells in patients with recently diagnosed diabetes mellitus types I and II]. Ter Arkh (1989) 0.76
[Cognitive impairment and anxiety-depressive disorders in patients with rheumatoid arthritis]. Zh Nevrol Psikhiatr Im S S Korsakova (2012) 0.76
Anticardiolipin antibodies in Sneddon's syndrome. Neurology (1990) 0.76
[Subclinical and clinical manifestations of atherosclerosis in antiphospholipid syndrome]. Ter Arkh (2008) 0.76
[Sneddon's syndrome and the primary antiphospholipid syndrome]. Ter Arkh (1993) 0.76
Sneddon's syndrome: cardiac pathology and antiphospholipid antibodies. Clin Exp Rheumatol (1991) 0.76
[Soluble CD40 ligand in systemic lupus erythematosus and antiphospholipid syndrome]. Ter Arkh (2006) 0.76
[Autoantibodies Against beta(1)-Adrenoreceptors in Patients With Cardiac Rhythm Disorders. Prevalence and Possible Role in Development of Arrhythmia]. Kardiologiia (2004) 0.76
[Differential diagnosis of Wegener's granulomatosis and extranodal NK/T-cell lymphoma, nasal type]. Ter Arkh (2012) 0.76
[Pharmacotherapy of rheumatoid arthritis: the 21st century]. Klin Med (Mosk) (2005) 0.75
[Combined medication ARTRA in the treatment of osteoarthrosis]. Ter Arkh (2005) 0.75
[The renin-angiotensin-aldosterone system and arterial hypertension in patients with rheumatoid arthritis]. Klin Med (Mosk) (1991) 0.75
[Clinical significance of antibodies to the smooth musculature in chronic active hepatitis]. Klin Med (Mosk) (1980) 0.75
[Morphological and immunohistochemical changes in the kidneys and skin in systemic lupus erythematosus during the course of treatment]. Revmatologiia (Mosk) (1983) 0.75
[Present problems of neuroimmunology]. Vestn Ross Akad Med Nauk (1994) 0.75
[Diagnosis of lesions of the central nervous system in patients with systemic lupus erythematosus]. Revmatologiia (Mosk) (1992) 0.75
[Clinico-pathogenetic aspects of Felty's syndrome]. Ter Arkh (1983) 0.75
[Clinico-immunologic characteristics of complicated and uncomplicated yersiniosis]. Vestn Akad Med Nauk SSSR (1989) 0.75
[Controlled trial of cyclophosphamide, azathioprine and chlorambucil in lupus nephritis (the double-blind method)]. Vopr Revm (1982) 0.75
[Clinico-genetic associations in systemic lupus erythematosus]. Ter Arkh (1981) 0.75
[Lesions of the central nervous system in systemic lupus erythematosus in the computerized-tomographic image]. Klin Med (Mosk) (1989) 0.75
[Inhibitory effect of sera from patients with rheumatic diseases on EA-rosette formation]. Ter Arkh (1983) 0.75
[Hepatitis B surface antigen in chronic active hepatitis and primary biliary cirrhosis]. Sov Med (1978) 0.75
[Objective evaluation of remote results of treatment of systemic lupus erythematosus]. Ter Arkh (1977) 0.75
[Blood serum glycosaminoglycans in assessing the degree of activity in systemic lupus erythematosus]. Revmatologiia (Mosk) (1988) 0.75
[An assessment of tissue microcirculation in patients with aseptic femur head necrosis in rheumatoid arthritis]. Ter Arkh (1994) 0.75
[Diclonate P in rheumatoid arthritis]. Ter Arkh (1994) 0.75
[The Tauredon treatment of rheumatoid arthritis patients: its efficacy and tolerance when used long term]. Ter Arkh (1996) 0.75
[Clinico-immunological characteristics of digital rheumatoid arteritis]. Ter Arkh (1982) 0.75
[Catabolic enzymes of the connective tissue in clinical aspects and pathogenesis of lupus-nephritis]. Sov Med (1974) 0.75
[Clinico-diagnostic aspects of rheumatic polymyalgia (literature review and case reports)]. Ter Arkh (1981) 0.75
[Clinical variants in the course and activity of lupus nephritis]. Ter Arkh (1971) 0.75
[The clinico-immunological characteristics of central nervous system involvement in systemic lupus erythematosus: the relationship with antibodies to cardiolipin]. Ter Arkh (1992) 0.75
[Circulating immune complexes in rheumatic diseases]. Ter Arkh (1981) 0.75
[Study of the peripheral blood lymphocytes in systemic lupus erythematosus of different degree of activity]. Ter Arkh (1978) 0.75
[Hyperuricemia, gout and gout-induced nephropathy]. Ter Arkh (1980) 0.75
[Clinico-pathogenetic factors in the development of immune complex disease]. Ter Arkh (1980) 0.75
[Effect of hemosorption on the course of autoimmune diseases with predominant involvement of the skin]. Klin Med (Mosk) (1982) 0.75
[Diagnostic possibilities of a test of blood neutrophil damage in various forms of yersiniosis in man]. Vestn Akad Med Nauk SSSR (1989) 0.75
[Antibodies to extractable nuclear antigens in rheumatic diseases]. Ter Arkh (1980) 0.75
[Combined syndromes of diffuse connective tissue diseases]. Vopr Revm (1978) 0.75
[The long-term parenteral use of cyclophosphane in treating patients with systemic lupus erythematosus and central nervous system involvement]. Ter Arkh (1995) 0.75
[Gerontological and geriatric problems of nephrology]. Ter Arkh (1981) 0.75
[Hemoperfusion through activated charcoal in the complex treatment of systemic lupus erythematosus]. Ter Arkh (1981) 0.75
[Active forms of oxygen and pathogenesis of rheumatoid arthritis and systemic lupus erythematosus]. Vestn Ross Akad Med Nauk (1996) 0.75
[Circulating immune complexes and clinico-immunologic subtypes of systemic lupus erythematosus. II]. Ter Arkh (1989) 0.75
[Cerebral vasculitis complicated with ruptured aneurysm of the basilar artery in a patient with systemic lupus erythematosus]. Klin Med (Mosk) (1993) 0.75
[Quantitative characteristic of circulating immune complexes in patients with lupus erythematosus and central nervous system disorders]. Klin Med (Mosk) (1991) 0.75
[Study of rheumatic diseases and international cooperation]. Vopr Revm (1979) 0.75
[Systemic lupus erythematosus with involvement of the central nervous system]. Klin Med (Mosk) (1989) 0.75
[Mixed connective tissue disease]. Ter Arkh (1982) 0.75
[Intravenous administration of high doses (pulse therapy) of methylprednisolone in lupus nephritis]. Ter Arkh (1983) 0.75
[Clinico-instrumental methods of diagnosing aseptic femur head necrosis in patients with systemic lupus erythematosus]. Ter Arkh (1988) 0.75
[Effect of hemosorption on the level of circulating immune complexes in diseases of the internal organs (I)]. Ter Arkh (1982) 0.75
[Role of the immunofluorescence technic in diagnosis of chronic liver diseases]. Ter Arkh (1978) 0.75
[The results of the dynamic observation of patients with reactive Yersinia arthritis]. Ter Arkh (1991) 0.75
[Immunomorphological changes in the skin of patients with systemic lupus erythematosus and the effect of cytostatic therapy]. Ter Arkh (1981) 0.75
[Circulating immune complexes (PEG tests) in systemic lupus erythematosus]. Ter Arkh (1982) 0.75
[The rheumatic complications of pseudotuberculosis in a newly arrived population in Siberia]. Ter Arkh (1991) 0.75